Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Alterations in Muscle Tone lll

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Metabolic Impact of Nonalcoholic Fatty Liver Disease on Cognitive Dysfunction: A Comprehensive Clinical and Pathophysiological Review.

International journal of molecular sciences·2024

Same author

The Gut-Liver-Brain Axis: From the Head to the Feet.

International journal of molecular sciences·2023

Same author

Treatment of a Severe Form of Euglycemic Ketoacidosis in a Patient Treated with SGLT-2 Inhibitors with the Aid of Somatostatin.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia·2023

Same author

Gut Microbes Meet Machine Learning: The Next Step towards Advancing Our Understanding of the Gut Microbiome in Health and Disease.

International journal of molecular sciences·2023

Same author

Celiac Disease and Neurological Manifestations: From Gluten to Neuroinflammation.

International journal of molecular sciences·2022

Same author

Bilirubin Prevents the TH<sup>+</sup> Dopaminergic Neuron Loss in a Parkinson's Disease Model by Acting on TNF-α.

International journal of molecular sciences·2022

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rivastigmine and Parkinson dementia complex.

Rita Moretti¹, Paola Torre, Cristina Vilotti

¹University of Trieste, Clinical Neurology, Department of Internal Medicine and Clinical Neurology, Ospedale di Cattinara, Strada di Fiume, 447 34149 Trieste, Italy. moretti@univ.trieste.it

Expert Opinion on Pharmacotherapy

|April 12, 2007

Summary

Parkinson's disease dementia (PDD) presents diagnostic challenges due to overlapping symptoms with Parkinson's disease. Rivastigmine shows promise in improving cognition and daily function for PDD patients.

Related Experiment Videos

Last Updated: Jul 15, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

Neurology
Geriatrics
Pharmacology

Background:

Parkinson's disease dementia (PDD) diagnosis is complicated by overlapping motor and cognitive impairments.
Cognitive deficits in PDD, particularly memory impairment, can be challenging to distinguish from other neurodegenerative conditions.
High mortality rates in PDD are associated with factors like hallucinations and institutionalization.

Purpose of the Study:

To evaluate the efficacy of rivastigmine in treating mild-to-moderate dementia associated with Parkinson's disease.
To assess the impact of rivastigmine on cognitive function and daily living activities in PDD patients.

Main Methods:

The study evaluated rivastigmine, a dual inhibitor of acetyl- and butyrylcholinesterases.
The treatment was assessed in patients with mild-to-moderate dementia associated with idiopathic Parkinson's disease.

Main Results:

Rivastigmine demonstrated potential benefits in improving cognition for patients with PDD.
The drug also showed positive effects on activities of daily living in the PDD patient group.
A clinically meaningful benefit was observed in a significant number of treated patients.

Conclusions:

Rivastigmine appears to be a beneficial symptomatic treatment for mild-to-moderate PDD.
Further research using pragmatic measures like quality of life assessments is warranted.
Addressing cognitive and functional decline in PDD is crucial for patient outcomes.